8-氨基-5,6,7,8-四氢异喹啉 | 497251-60-2

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 8-氨基-5,6,7,8-四氢异喹啉
• 中文别名: 5,6,7,8-四氢异喹啉-8-胺
• 英文名称: 5,6,7,8-Tetrahydroisoquinolin-8-amine
• CAS: 497251-60-2
• 化学式: C₉H₁₂N₂
• 分子量: 148.2
• InChiKey: BMARABOQKIKIRT-UHFFFAOYSA-N

物化性质

• 沸点：
  256.3±28.0 °C(Predicted)
• 密度：
  1.081±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933499090

文献信息

• [EN] SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] PYRROLO[1,2-A]PYRIMIDINES SUBSTITUÉES ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：LYSOSOMAL THERAPEUTICS INC

  公开号：WO2016073891A1

  公开（公告）日：2016-05-12

  The invention provides substituted pyrrolo[l,2-a]pyrimi dines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidines compounds described herein include substituted 2,4-dimethyl-N-phenylpyrrolo[l,2-a]pyrimidine-8-carboxamide compounds and variants thereof.

  该发明提供了取代的吡咯并[1,2-a]嘧啶和相关的有机化合物，包含这种化合物的组合物，医疗工具包，以及使用这种化合物和组合物治疗疾病的方法，例如高雪氏病、帕金森病、路易体病、痴呆症或多系统萎缩症等。本文描述的示例取代的吡咯并[1,2-a]嘧啶化合物包括取代的2,4-二甲基-N-苯基吡咯并[1,2-a]嘧啶-8-羧酰胺化合物及其变体。
• BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
  申请人：Xenon Pharmaceuticals Inc.

  公开号：US20180162868A1

  公开（公告）日：2018-06-14

  This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

  这项发明涉及苯磺酰胺化合物，作为其立体异构体、对映异构体、互变异构体或它们的混合物；或其药学上可接受的盐、溶剂合物或前药，用于治疗与电压门控钠通道相关的疾病或症状，如癫痫和/或癫痫发作障碍。
• [EN] INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF<br/>[FR] INHIBITEURS DE L'INTERACTION PROTÉINE-PROTÉINE DU DOMAINE BCL6 BTB ET LEURS UTILISATIONS
  申请人：ONTARIO INSTITUTE FOR CANCER RES OICR

  公开号：WO2019153080A1

  公开（公告）日：2019-08-15

  The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

  本申请涉及公式I（I）化合物或其药用可接受的盐、溶剂化合物和/或前药，包括含有这些化合物或药用可接受的盐、溶剂化合物和/或前药的组合物，以及在治疗可通过抑制与BCL6 BTB的相互作用可治疗的疾病、紊乱或状况中的各种用途，如癌症。
• [EN] NOVEL PRMT5 INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE PRMT5
  申请人：AMGEN INC

  公开号：WO2021163344A1

  公开（公告）日：2021-08-19

  Described herein are compounds of Formula I and pharmaceutically acceptable salt thereof, stereoisomers, tautomers as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders. Compounds of Formula I have the following structure: (I)

  本文描述了公式I的化合物及其药用盐、立体异构体、互变异构体以及其药用组合物。本发明的化合物对抑制PRMT5活性有用，并可能用于治疗增殖、代谢和血液疾病。公式I的化合物具有以下结构：(I)
• Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
  申请人：Array Biopharma, Inc.

  公开号：EP2573087A1

  公开（公告）日：2013-03-27

  Provided are compounds of Formula I wherein R2, R3, R13 , L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  提供了式 I 的化合物 其中 R2、R3、R13、L 和 D2 如说明书中所定义，可用于治疗和/或预防由葡萄糖激酶活性水平不足介导或可通过激活葡萄糖激酶治疗的疾病或紊乱，包括但不限于糖尿病、糖耐量受损、空腹血糖受损和空腹血糖升高，以及其它疾病和紊乱，如本文所讨论的疾病和紊乱。